XML 58 R47.htm IDEA: XBRL DOCUMENT v3.25.2
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2010
cvr
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Assets:            
Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag       Derivative assets(2)   Derivative assets(2)
Liabilities:            
Number of CVR series | cvr 4          
Transferred over Time | Phase 3 clinical trial            
Liabilities:            
Gross contract asset   $ 10,000   $ 10,000    
Minimum | Agenus Partnered Program | Discount Rate            
Liabilities:            
Discount rate (as a percent)   0.15   0.15   0.15
Maximum | Agenus Partnered Program | Discount Rate            
Liabilities:            
Discount rate (as a percent)   0.28   0.28   0.28
Maximum | Transferred over Time | Development, regulatory, & commercial milestones and tiered royalties            
Liabilities:            
Investments   $ 375,000   $ 375,000    
Metabasis            
Liabilities:            
Number of CVRs issued per acquiree share | cvr 4          
Number of CVRs issued from each CVR series | cvr 1          
Frequency of cash payments to CVR holders 6 months          
(Decrease) increase of mark-to-market adjustment of CVR liability   100 $ 1,100 1,900 $ 1,100  
Recurring            
Assets:            
Investments, fair value   150,851   150,851   $ 143,618
Investment in Viking common stock   26,500   26,500   40,240
Derivative asset   17,958   17,958   10,583
Total assets   195,309   195,309   194,441
Liabilities:            
Total liabilities   5,562   5,562   3,681
Recurring | Contingent liabilities | CyDex            
Liabilities:            
Contingent liabilities   351   351   383
Recurring | Contingent liabilities | Metabasis            
Liabilities:            
Contingent liabilities   5,211   5,211   3,298
Recurring | Level 1            
Assets:            
Investments, fair value   72,560   72,560   81,807
Investment in Viking common stock   26,500   26,500   40,240
Derivative asset   0   0   0
Total assets   99,060   99,060   122,047
Liabilities:            
Total liabilities   0   0   0
Recurring | Level 1 | Contingent liabilities | CyDex            
Liabilities:            
Contingent liabilities   0   0   0
Recurring | Level 1 | Contingent liabilities | Metabasis            
Liabilities:            
Contingent liabilities   0   0   0
Recurring | Level 2            
Assets:            
Investments, fair value   78,291   78,291   61,811
Investment in Viking common stock   0   0   0
Derivative asset   0   0   0
Total assets   78,291   78,291   61,811
Liabilities:            
Total liabilities   5,211   5,211   3,298
Recurring | Level 2 | Contingent liabilities | CyDex            
Liabilities:            
Contingent liabilities   0   0   0
Recurring | Level 2 | Contingent liabilities | Metabasis            
Liabilities:            
Contingent liabilities   5,211   5,211   3,298
Recurring | Level 3            
Assets:            
Investments, fair value   0   0   0
Investment in Viking common stock   0   0   0
Derivative asset   17,958   17,958   10,583
Total assets   17,958   17,958   10,583
Liabilities:            
Total liabilities   351   351   383
Recurring | Level 3 | Contingent liabilities | CyDex            
Liabilities:            
Contingent liabilities   351   351   383
Recurring | Level 3 | Contingent liabilities | Metabasis            
Liabilities:            
Contingent liabilities   $ 0   $ 0   $ 0